Page last updated: 2024-08-23

bromocriptine and cyclin d1

bromocriptine has been researched along with cyclin d1 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Deng, Q; Li, Z; Liang, J; Liu, Z; Shao, Z; Song, C; Wang, X; Xiao, Z; Yang, X; Zhang, K1
Li, Z; Liu, Z; Shao, Z; Song, C; Wang, X; Xiao, Z; Yang, X; Zhang, K1

Other Studies

2 other study(ies) available for bromocriptine and cyclin d1

ArticleYear
Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
    International journal of molecular medicine, 2021, Volume: 47, Issue:1

    Topics: Animals; bcl-X Protein; Bromocriptine; Cell Line, Tumor; Cyclin D1; Humans; Mice; Mice, Nude; Pimozide; Pituitary Neoplasms; Prolactinoma; Rats; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays

2021
Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
    International journal of medical sciences, 2020, Volume: 17, Issue:18

    Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Hypophysectomy; Male; MAP Kinase Signaling System; Middle Aged; Neoplasm Recurrence, Local; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Rats; Receptors, Prolactin; Young Adult

2020